What happened
On July 31, 2026, the FDA approved lutetium Lu 177 vipivotide tetraxetan, marketed as Pluvicto by Novartis Pharmaceuticals Corporation, in combination with androgen receptor pathway inhibitor, or ARPI, therapy for adults with prostate-specific membrane antigen-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, a setting the agency said was previously referred to as metastatic hormone-sensitive prostate cancer. The label requires patient selection using Locametz, with active ingredient gallium Ga 68 gozetotide, or another approved PSMA PET product based on PSMA expression in tumors.
The approval was based on the randomized, multicenter, open-label PSMAddition trial, which assigned 572 patients to Pluvicto plus an ARPI and 572 to an ARPI alone. The major efficacy endpoint was radiographic progression-free survival by blinded independent central review, and the trial showed a statistically significant improvement for the Pluvicto arm, with a hazard ratio of 0.72 (95% CI: 0.58, 0.90; p-value 0.002). Median rPFS was not reached in either arm, and overall survival data were immature at the current analysis.
The recommended dose is 7.4 GBq (200 mCi) every six weeks for six doses, or until disease progression or unacceptable toxicity. FDA said the review finished one month ahead of the goal date.
Why it matters
Pluvicto now moves into an earlier metastatic prostate cancer population and, just as important, ties use to PSMA imaging and combination treatment with an ARPI. For Novartis, the practical implication is broader use anchored to a defined diagnostic workflow. For providers and payers, this is not simply an add-on oncology approval.
It links treatment access to PSMA PET confirmation and brings a radiopharmaceutical with known warnings for radiation exposure, myelosuppression, renal toxicity, embryo-fetal toxicity, and infertility into a less heavily pretreated setting. A different setting. Detailed drug monographs are at ClinicalRx.ai.
The investor read is likely straightforward: FDA accepted a radiographic progression-free survival benefit here, while overall survival remains immature. That usually shifts attention to uptake, operational capacity, and how quickly the market absorbs a six-dose radioligand regimen alongside investigator’s choice of ARPI, including abiraterone, apalutamide, enzalutamide, darolutamide, or another ARPI.
The next watch item is whether earlier-line use changes treatment sequencing in a meaningful way or remains bounded by imaging availability and radiopharmaceutical delivery logistics. For employer-side PBM benchmarking, see RxPBM.ai.